NASDAQ:GRTS Gritstone bio (GRTS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free GRTS Stock Alerts $2.57 -0.23 (-8.21%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.52▼$2.9450-Day Range$2.02▼$2.8652-Week Range$1.14▼$3.33Volume2.26 million shsAverage Volume1.82 million shsMarket Capitalization$252.04 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Gritstone bio alerts: Email Address Gritstone bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside133.5% Upside$6.00 Price TargetShort InterestBearish9.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.94) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.05 out of 5 starsMedical Sector831st out of 939 stocksBiological Products, Except Diagnostic Industry142nd out of 156 stocks 3.5 Analyst's Opinion Consensus RatingGritstone bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Gritstone bio has a forecasted upside of 133.5% from its current price of $2.57.Amount of Analyst CoverageGritstone bio has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.86% of the float of Gritstone bio has been sold short.Short Interest Ratio / Days to CoverGritstone bio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Gritstone bio has recently increased by 7.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGritstone bio does not currently pay a dividend.Dividend GrowthGritstone bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTS. Previous Next 2.5 News and Social Media Coverage News SentimentGritstone bio has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Gritstone bio this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for GRTS on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows9 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.61% of the stock of Gritstone bio is held by insiders.Percentage Held by Institutions48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gritstone bio are expected to decrease in the coming year, from ($0.94) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone bio is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone bio is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone bio has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Gritstone bio Stock (NASDAQ:GRTS)Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Read More GRTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTS Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comGritstone bio Sees Unusually Large Options Volume (NASDAQ:GRTS)March 28, 2024 | seekingalpha.comGRTS Gritstone bio, Inc.March 29, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSMarch 18, 2024 | msn.comDo Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?March 8, 2024 | finance.yahoo.comGritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | finance.yahoo.comGritstone Bio Inc (GRTS) Reports Fiscal Year 2023 Financial Results and Corporate UpdatesMarch 7, 2024 | finance.yahoo.comGritstone bio Full Year 2023 Earnings: Beats ExpectationsMarch 29, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 5, 2024 | globenewswire.comGritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 5, 2024 | finance.yahoo.comGRTS Apr 2024 0.500 putMarch 5, 2024 | finance.yahoo.comGRTS Aug 2024 0.500 putMarch 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSMarch 1, 2024 | benzinga.comWhy Is Gritstone Bio Stock Trading Lower?March 1, 2024 | bizjournals.comDomino effect around next-generation Covid vaccine trial leads Gritstone to cut 40% of staffFebruary 29, 2024 | marketwatch.comGritstone Bio Shares Tumble 23% After Cutting 40% of WorkforceFebruary 29, 2024 | marketwatch.comGritstone Bio To Cut 40% Of WorkforceFebruary 29, 2024 | msn.comGritstone to cut 40% of staff due to funding delay, stock plunges 23%February 29, 2024 | finance.yahoo.comGritstone bio Announces Workforce ReductionFebruary 22, 2024 | finance.yahoo.comGRTS Mar 2024 1.000 putFebruary 22, 2024 | finance.yahoo.comGRTS Apr 2024 5.000 callFebruary 21, 2024 | finance.yahoo.comGritstone bio to Participate in Upcoming Investor and Scientific ConferencesFebruary 21, 2024 | globenewswire.comGritstone bio to Participate in Upcoming Investor and Scientific ConferencesFebruary 18, 2024 | finance.yahoo.comGRTS Mar 2024 2.500 putFebruary 17, 2024 | finance.yahoo.comGRTS Mar 2024 1.500 putFebruary 14, 2024 | finance.yahoo.comGRTS Apr 2024 2.000 callFebruary 14, 2024 | finance.yahoo.comGRTS Feb 2024 2.000 callSee More Headlines Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRTS CUSIPN/A CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees231Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+133.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-138,490,000.00 Net Margins-847.24% Pretax Margin-847.34% Return on Equity-147.22% Return on Assets-69.46% Debt Debt-to-Equity Ratio0.77 Current Ratio3.20 Quick Ratio3.20 Sales & Book Value Annual Sales$16.34 million Price / Sales15.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book4.76Miscellaneous Outstanding Shares98,070,000Free Float93,545,000Market Cap$252.04 million OptionableOptionable Beta0.39 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Andrew R. Allen BCh (Age 58)BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director Comp: $983.44kMr. Erin E. Jones M.S. (Age 52)Executive VP & COO Comp: $658.01kDr. Karin Jooss Ph.D. (Age 58)Executive VP and Head of Research & Development Comp: $706.07kMs. Vassiliki Economides (Age 43)Executive VP & CFO Mr. James ChoChief Accounting OfficerGeorge MacDougallDirector of Investor Relations & Corporate CommunicationsMs. Stacy ProctorExecutive VP & Chief People OfficerDr. Matthew J. Hawryluk M.B.A. (Age 46)Ph.D., Executive VP & Chief Business Officer More ExecutivesKey CompetitorsSutro BiopharmaNASDAQ:STROCompass TherapeuticsNASDAQ:CMPXScilexNASDAQ:SCLXCentury TherapeuticsNASDAQ:IPSCCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 358,075 shares on 3/11/2024Ownership: 4.503%Goldman Sachs Group Inc.Sold 48,557 shares on 3/1/2024Ownership: 0.144%Barclays PLCBought 105,042 shares on 2/15/2024Ownership: 0.149%Citadel Advisors LLCBought 38,200 shares on 2/15/2024Ownership: 0.000%Wexford Capital LPBought 12,660 shares on 2/15/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions GRTS Stock Analysis - Frequently Asked Questions Should I buy or sell Gritstone bio stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTS shares. View GRTS analyst ratings or view top-rated stocks. What is Gritstone bio's stock price target for 2024? 3 brokers have issued 12-month price targets for Gritstone bio's stock. Their GRTS share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts. How have GRTS shares performed in 2024? Gritstone bio's stock was trading at $2.04 at the beginning of 2024. Since then, GRTS shares have increased by 26.0% and is now trading at $2.57. View the best growth stocks for 2024 here. Are investors shorting Gritstone bio? Gritstone bio saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 8,820,000 shares, an increase of 7.3% from the February 29th total of 8,220,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 4.3 days. Approximately 9.9% of the company's shares are short sold. View Gritstone bio's Short Interest. When is Gritstone bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GRTS earnings forecast. How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $10.38 million for the quarter, compared to analysts' expectations of $4.80 million. Gritstone bio had a negative trailing twelve-month return on equity of 147.22% and a negative net margin of 847.24%. What ETF holds Gritstone bio's stock? Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio. What is Andrew Allen's approval rating as Gritstone bio's CEO? 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL). When did Gritstone bio IPO? Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. Who are Gritstone bio's major shareholders? Gritstone bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.63%), Vanguard Group Inc. (4.50%), Point72 Asset Management L.P. (4.17%), Frazier Life Sciences Management L.P. (1.08%), Northern Trust Corp (0.77%) and Charles Schwab Investment Management Inc. (0.28%). Insiders that own company stock include Erin Jones and Vassiliki Economides. View institutional ownership trends. How do I buy shares of Gritstone bio? Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRTS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.